US Patent 8524867 Optimized antibodies that target CD19
Patent 8524867 was granted and assigned to Xencor on September, 2013 by the United States Patent and Trademark Office.
All edits
Edits on 11 Sep, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 17 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 12 Mar, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 11 Oct, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 27 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 13 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 5 Jul, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 May, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 21 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 08524867 Optimized antibodies that target CD19 US Patent 8524867 Optimized antibodies that target CD19
Infobox
Patent Number
085248670
Patent Number
85248670
Edits on 28 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
085248670
Date of Patent
September 3, 2013
0Patent Application Number
123772510
Date Filed
August 14, 2007
0Patent Primary Examiner
Edits on 17 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 08524867 Optimized antibodies that target CD19
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
08524867
Date of patent
September 3, 2013
Patent application number
12377251
Date Filed
August 14, 2007
Patent primary examiner
Find more entities like US Patent 8524867 Optimized antibodies that target CD19
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
